Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Saraceni F, Beohou E, Labopin M, Arcese W, Bonifazi F, Stepensky P, Aljurf M, Bruno B, Pioltelli P, Passweg J, Sociè G, Santarone S, Yakoub-Agha I, Lanza F, Savani BN, Mohty M, Nagler A; Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Saraceni F, et al. Am J Hematol. 2018 Oct;93(10):1211-1219. doi: 10.1002/ajh.25225. Epub 2018 Aug 15. Am J Hematol. 2018. PMID: 30033639 Free article.
Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.
Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socié G, Golmard JL, Jouet JP; French Society of Bone Marrow Transplantation and Cell Therapy. Yakoub-Agha I, et al. J Clin Oncol. 2006 Dec 20;24(36):5695-702. doi: 10.1200/JCO.2006.08.0952. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116940
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M, Le QH, Mohty M, Prébet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D. Michallet M, et al. Exp Hematol. 2008 May;36(5):535-44. doi: 10.1016/j.exphem.2008.01.017. Epub 2008 Mar 17. Exp Hematol. 2008. PMID: 18346838 Free article.
Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.
Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M; Société Française de Greffe de Moëlle et de Thérapie Cellulaire. Le Gouill S, et al. J Clin Oncol. 2008 May 10;26(14):2264-71. doi: 10.1200/JCO.2007.14.1366. Epub 2008 Apr 7. J Clin Oncol. 2008. PMID: 18390969
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18. Lancet Oncol. 2009. PMID: 19695955 Clinical Trial.
Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I, Mohty M, Robin M, Tabrizi R, Clement L, Bilger K, Larosa F, Contentin N, Huyn A, François S, Bulabois CE, Ceballos P, Bourrhis JH, Buzyn A, Cornillon J, Guillerm G, de Revel T, Bay JO, Guilhot F, Milpied N. Sirvent A, et al. Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85. doi: 10.1016/j.bbmt.2009.09.002. Epub 2009 Sep 8. Biol Blood Marrow Transplant. 2010. PMID: 19744569 Free article.
Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.
Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, Fegueux N, Guilhot F, Lapusan S, Gratecos N, Cahn JY, Socié G, Yakoub-Agha I, Huynh A, Francois S, Bay JO, Maury S, Buzyn A, Contentin N, Mohty M. Chevallier P, et al. Biol Blood Marrow Transplant. 2012 Feb;18(2):289-94. doi: 10.1016/j.bbmt.2011.07.013. Epub 2011 Jul 23. Biol Blood Marrow Transplant. 2012. PMID: 21781949 Free article. Clinical Trial.
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM). Yakoub-Agha I, et al. Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4. Eur J Haematol. 2012. PMID: 22023551 Clinical Trial.
558 results